ACAAI Publishes New Cough Management Guidelines
The American College of Allergy, Asthma and Immunology (ACAAI) has published two new clinical "yardsticks" for cough management and managing eosinophilic esophagitis.
The American College of Allergy, Asthma and Immunology (ACAAI) has published two new clinical "yardsticks" for cough management and managing eosinophilic esophagitis.
Gefapixant (MK-7264) is an investigational, orally administered, selective P2X3 receptor antagonist for the potential treatment of refractory or unexplained chronic cough.
FeNO may be useful for diagnosing cough variant asthma in patients with chronic cough who have normal spirometry.
Scientists have found that codeine could be no more effective than an inactive placebo compound at treating cough.
Read More